Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Quinonemethide triterpenoids and pharmaceutical compositions for the treatment of refractory rheumatoid arthritis

A quinone methyl triterpenoid, rheumatoid technology, applied in the field of treatment of rheumatoid arthritis

Active Publication Date: 2019-01-18
MACAU UNIV OF SCI & TECH
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This multidrug resistance may be intrinsic or acquired

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quinonemethide triterpenoids and pharmaceutical compositions for the treatment of refractory rheumatoid arthritis
  • Quinonemethide triterpenoids and pharmaceutical compositions for the treatment of refractory rheumatoid arthritis
  • Quinonemethide triterpenoids and pharmaceutical compositions for the treatment of refractory rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0147] Example 1: Induction of autophagy

[0148] In these examples, all rheumatoid arthritis synovial fibroblasts (RASFs) were isolated from rheumatoid patients, while immortal rheumatoid arthritis synovial fibroblasts (RAFLS) were isolated from primary rheumatoid arthritis synovial fibroblasts (RAFLS). Derived from membranous fibroblasts (RASFs).

[0149] In order to detect the endogenous expression of autophagy-related protein LC3-II, RASFs or RAFLS cell lines were treated and fixed with specified concentrations of tripterine (CEL) at specific times, and then LC3-II was used to fluorescently stain the binding protein against Mouse antibody, photographed under a fluorescent microscope using red fluorescence.

[0150] Analysis by flow cytometry. Cell death and viability were measured using Annexin V staining kit (BD Biosciences, San Jose, CA, USA).

[0151] Briefly, RAFLS were treated with 0-2 μM tripterine for 24 hours. Then the cells were harvested and stained with FITC...

example 2

[0153] Example 2: Mobilization of cytosolic calcium to induce autophagy

[0154] The calcium ion concentration in the cytoplasm was dynamically measured using the FLIPR calcium 6 kit (Molecular Devices) according to the kit instructions. Briefly, RASFs were seeded at a density of 10,000 cells per well in a black-walled / white-bottomed 96-well plate (Tewksbury, MA, USA) for 24 hours, after which calcium 6 reagent was directly added to the cells, at 37 °C and 5% carbon dioxide for 2 hours. Immediately after adding tripterine or thapsigargin at different concentrations into the 96-well plate, data was collected using a Spectramax Paradigm multimode microplate reader (Molecular Devices), and the values ​​were read at room temperature with a reading interval of 1 second.

[0155] Cytosolic calcium levels were measured using flow cytometry. Intracellular free calcium is measured by a Fluo-3 fluorescent dye. Briefly, RAFLS were treated with Celastrol (1 μM) for 4 hours, washed twic...

example 3

[0161] Example 3: Inhibitory effect of tripterine on apoptosis-deficient RAFLS

[0162] RAFLS transfected with mutant p53 were lysed with RIPA lysis buffer. Protein concentrations were determined using the Bio-Rad protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Cell lysate samples were electrophoresed on SDS polyacrylamide gels and transferred to enhanced chemiluminescent nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ) and blocked with 5% nonfat dry milk protein for 1 hour. The membrane was then incubated overnight at 4°C with an apoptotic marker antibody. Antibody binding was visualized by ECL Western Blot Detection Reagent (Invitrogen, Paisley, Scotland, UK) with a peroxidase-conjugated secondary antibody. Band intensities were quantified by using the software ImageJ (NIH, Bethesda, MD, USA).

[0163] Perform cytotoxicity test. All test compounds were dissolved in DMSO at a final concentration of 50 mmol / L and stored at -20°C until use. Cy...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Application of a quinonemethide triterpenoid or a pharmaceutically tolerable salt, solvate or anhydrate thereof in preparing medicine for the treatment of refractory rheumatoid arthritis, and application in medicine for inducing autophagy in a synovial fibroblast. Further a pharmaceutical composition includes an effective dose of a quinonemethide triterpenoid and an anti-arthritis compound. The quinonemethide triterpenoid is suitable to treat refractory rheumatoid arthritis (RA), in particular ABC-protein-dependent RA and apoptosis-deficient RA. The quinonemethide triterpenoid also possesses significant inhibitory effects on the growth of synovial fibroblasts, in particular modulating the calcium homeostasis in multidrug-resistant rheumatoid arthritis synovial fibroblasts.

Description

technical field [0001] The present invention relates to a method for treating rheumatoid arthritis, particularly refractory rheumatoid arthritis, by administering quinonemethyl triterpenoids. The present invention also relates to a pharmaceutical composition comprising quinonemethyl triterpenoids and anti-arthritic compounds, especially for treating refractory rheumatoid arthritis. Background technique [0002] Drug resistance has been an eternal obstacle to the treatment of rheumatoid arthritis, especially refractory rheumatoid arthritis. Resistance to classical therapeutic drugs is mainly divided into two categories: intrinsic drug resistance caused by heredity and acquired drug resistance caused by selection pressure caused by exposure to drugs. In fact, intrinsic drug resistance is more common in inflammatory diseases such as rheumatoid arthritis (RA). Rheumatoid arthritis synovial fibroblasts (RASFs) have antiapoptotic properties due to low expression levels of the tu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/56A61K45/06A61P19/02A61P29/00
CPCA61K45/06A61P19/02A61P29/00A61K31/56A61K2300/00
Inventor 刘良黄锦伟罗婉君邱聪龄
Owner MACAU UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com